Terminated EARLY_PHASE1 INTERVENTIONAL 1-arm NCT02411643

Molecular Effects of Topical Calcipotriene on Morphea

Sponsor: Northwestern University

Conditions Localized Scleroderma Morphea

Interventions topical calcipotriene 0.005% ointment

Updated 8 times since 2017 Last updated: Dec 22, 2017 Started: Mar 31, 2015 Primary completion: Apr 30, 2016 Completion: Apr 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Accrual incomplete/Investigator left institution

Other terminated trials from Northwestern University

See all terminations from Northwestern University

This EARLY_PHASE1 trial investigates Localized Scleroderma and Morphea and is currently terminated or withdrawn. Northwestern University leads this study, which shows 8 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Terminated EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated EARLY_PHASE1
Jan 2023 — Jul 2024 [monthly]

Terminated EARLY_PHASE1
Dec 2022 — Jan 2023 [monthly]

Terminated EARLY_PHASE1
Jan 2021 — Dec 2022 [monthly]

Terminated EARLY_PHASE1

▶ Show 3 earlier versions

Oct 2018 — Jan 2021 [monthly]

Terminated EARLY_PHASE1

Phase: NA → EARLY_PHASE1
Jun 2018 — Oct 2018 [monthly]

Terminated NA
Jan 2017 — Jun 2018 [monthly]

Terminated NA

First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Northwestern University

Data source: Northwestern University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States